Vanda Pharmaceuticals Inc.

Stocks

VNDA

US9216591084

Market Closed - Nasdaq Other stock markets 21:00:00 15/06/2026 BST			5-day change	1st Jan Change
5.880 ^USD	+0.17%		-2.49%	-33.33%

05-07	Vanda Pharmaceuticals Inc., Q1 2026 Earnings Call, May 06, 2026
05-06	Vanda Pharmaceuticals Inc. Raises Revenue Guidance for the Full-Year 2026	CI

Transcript : Vanda Pharmaceuticals Inc., Q1 2026 Earnings Call, May 06, 2026

Published on 05/07/2026 at 09:51 am BST - Modified on 05/18/2026 at 03:55 pm BST

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Thank you for standing by. My name is Jordan, and I'll be your conference operator today. At this time, I would like to welcome everyone to the Q1 2026

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Vanda Pharmaceuticals Inc.

05-07	Vanda Pharmaceuticals Inc., Q1 2026 Earnings Call, May 06, 2026
05-06	Vanda Pharmaceuticals Inc. Raises Revenue Guidance for the Full-Year 2026	CI
05-06	Vanda Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-04	Sector Update: Health Care Stocks Softer Late Afternoon	MT
05-04	Vanda Pharmaceuticals Launches Motion Sickness Drug Nereus in US	MT
05-04	Vanda Pharmaceuticals announces U.S. commercial availability of Nereus(TM) (tradipitant), the first new pharmacologic treatment for people with motion sickness in more than 40 years	RE
05-01	Vanda Pharmaceuticals US availability of Nereus for people with motion sickness	RE
05-01	Vanda Pharmaceuticals Inc. Announces Commercial Availability of Nereus (Tradipitant) for Motion Sickness Prevention in the United States	CI
04-22	Vanda Pharmaceuticals Inc. Appoints Charles Duncan to Its Board of Directors, Effective April 22, 2026	CI
04-13	Geron Corporation Announces Appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary	CI
04-09	Vanda Asks FDA to Withdraw Proposal Extending Drug Review Timelines	MT
04-08	Vanda Pharmaceuticals Starts Study of Nereus to Address GLP-1 Side Effects	MT
04-08	Vanda Pharmaceuticals announces initiation of the Thetis study, a clinical trial of Nereus(TM) for the prevention of vomiting induced by GLP-1 receptor agonists	RE
04-08	Vanda Pharmaceuticals Inc. Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS? for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists	CI
04-02	Vanda Pharmaceuticals Inc. Announces Resignation of Timothy Williams as Senior Vice President, General Counsel and Secretary, Effective April 10, 2026	CI